BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 6683993)

  • 1. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
    de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
    Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride.
    Cafaggi S; Esposito M; Parodi B; Vannozzi MO; Viale M; Pellecchia C; Fulco RA; Merlo F; Zicca A; Cadoni A
    Anticancer Res; 1992; 12(6B):2285-92. PubMed ID: 1295476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
    Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
    Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
    Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
    Hacker MP; Khokhar AR; Brown DB; McCormack JJ; Krakoff IH
    Cancer Res; 1985 Oct; 45(10):4748-53. PubMed ID: 4040806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
    Frühauf S; Zeller WJ
    Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
    Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
    Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.
    Steerenberg PA; Storm G; de Groot G; Claessen A; Bergers JJ; Franken MA; van Hoesel QG; Wubs KL; de Jong WH
    Cancer Chemother Pharmacol; 1988; 21(4):299-307. PubMed ID: 3370737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
    Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
    Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Water-soluble N-substituted iminodiacetato(1,2-diaminocyclohexane)-platinum(II) complexes as potential antitumor agents.
    Hacker MP; Khokhar AR; Krakoff IH; Brown DB; McCormack JJ
    Cancer Res; 1986 Dec; 46(12 Pt 1):6250-4. PubMed ID: 3779645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat.
    van Hoesel QG; Steerenberg PA; Crommelin DJ; van Dijk A; van Oort W; Klein S; Douze JM; de Wildt DJ; Hillen FC
    Cancer Res; 1984 Sep; 44(9):3698-705. PubMed ID: 6744286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma.
    Berry JP; Pauwells C; Tlouzeau S; Lespinats G
    Cancer Res; 1984 Jul; 44(7):2864-8. PubMed ID: 6539165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats.
    Baldew GS; van den Hamer CJ; Los G; Vermeulen NP; de Goeij JJ; McVie JG
    Cancer Res; 1989 Jun; 49(11):3020-3. PubMed ID: 2720662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.
    van Hoesel QG; Steerenberg PA; Vos JG; Hillen FC; Dormans JA
    J Natl Cancer Inst; 1984 May; 72(5):1141-50. PubMed ID: 6585590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
    Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
    Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
    Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.
    Baba H; Siddik ZH; Strebel FR; Jenkins GN; Bull JM
    Cancer Res; 1989 Dec; 49(24 Pt 1):7041-4. PubMed ID: 2582445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.